Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
24 January 2021 | Story Lacea Loader
Ivermectin

FARMOVS, a wholly owned clinical research company of the University of the Free State (UFS), together with several medical and scientific experts at the university, is currently in the process of preparing a clinical trial protocol to determine the efficacy of Ivermectin for COVID-19 in a randomised, controlled study according to the requirements of the legal professions, in order to submit it for approval to the relevant national regulatory authority.

FARMOVS is a South African specialty full-service clinical research organisation conducting ICH-GCP-compliant Phase I to IV clinical trials. FARMOVS’ competitive advantage is its wealth of bioequivalence and Phase I experience and expertise, patient recruitment success, and a clinical research facility with the only onsite ISO (International Organization for Standardization) and GLP (Good Laboratory Practice) certified bioanalytical laboratory on the African continent.

By participating in the preparation of the clinical trial protocol, FARMOVS and the UFS remain supportive of and committed to contributing to the development of treatments and treatment strategies to battle the COVID-19 pandemic. Should the clinical trial protocol be approved by the relevant national regulatory authority, the UFS will be the first university in South Africa to attempt such a study.

The university management is aware of a WhatsApp voice clip being circulated, in which reference is made to a particular meeting, and mention is made of the role the institution is playing in establishing the efficacy of Ivermectin for COVID-19. The voice clip is premature and was shared with a small group, from where it went viral. The voice clip is also not factual – specifically regarding the university and its alleged opinion pertaining to the usage and need for scientific investigation into the matter.  

The UFS is committed to rigorous science and evidence-based research, and both FARMOVS and the university fully support the published opinions and guidelines of the South African Health Products Regulatory Authority (SAHPRA) and the scientific advisory boards established by the scientific community, as well as the stance of the South African government on Ivermectin for COVID-19.

Released by:
Lacea Loader (Director: Communication and Marketing)
Telephone: +27 51 401 2584 | +27 83 645 2454
Email: news@ufs.ac.za | loaderl@ufs.ac.za

News Archive

UFS research on yeast nanorobotics
2006-05-09

Ten members from the University of the Free State's (UFS) Lipid Biotechnology Research Group in the Department of Microbial, Biochemical and Food Biotechnology will be presenting their research  on yeast nanorobotics (nanotechnology) at three international conferences in Europe during May and June 2006.

 

It is one of the biggest group of students from the department to present their research overseas.  

The conferences to be attended include the 2nd International Conference on Non Mammalian Eicosanoids, Bioactive Lipids and Plant Oxylipins held in Berlin, Germany; the 3rd European Conference on Computational Mechanics (ECCM-2006) held in Lisbon, Portugal and the 25th International Specialised Symposium on Yeasts (ISSY 2006) held in Helsinki, Finland.  The UFS Lipid Biotechnology Group is also co-organising the conference in Berlin.

The group members are in front from the left Ms Chantel Swart (M Sc student), Ms Ntsoaki Leeuw (M Sc student) and Ms Monique Goldblatt (M Sc student).
Middle from the left Mr Olihile Sebolai (Ph D student and recipient of the Free State Premier Excellence Award), Ms Ané van Heerden (M Sc student) and Dr Catrine Strauss (post-doctoral student).
At the back are from the left Mr Desmond Ncango (M Sc), Dr Carlien Pohl (Senior Researcher), Prof Pieter van Wyk (Head: UFS Center for Confocal and Electron Microscopy) and Prof Lodewyk Kock (Head: UFS Lipid Biotechnology Group).
Photo: Stephen Collett

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept